# BPC-157 TB-500: The Wolverine Blend, Shown Straight From the Record > BPC-157 TB-500 is the two-peptide 'Wolverine' blend pairing a cytoprotective peptide with an actin-binding fragment. Strong single-compound preclinical data, no controlled combination trial. A cited safety brief. Two specimens on one studio table: BPC-157 is the cytoprotective, pro-angiogenic peptide; TB-500 is the actin-binding fragment of Thymosin Beta-4. The single-compound preclinical data is real. The combination has no controlled trial, and one honest safety signal is flagged. ## Two specimens, one repair rationale BPC-157 TB-500 is the research-community name for a two-peptide tissue-repair blend — marketed and discussed as the "Wolverine" stack — that pairs BPC-157 with TB-500. It is not a single chemical entity. It has no molecular weight, CAS number, or approved indication of its own; the values below describe its two constituents [1][3]. This site reads the blend the way a studio reads a product: each peptide set down on its own plinth, shown accurately, with the gaps and the one flagged safety signal left in plain light. The first specimen is BPC-157 (Body Protection Compound 157), a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV, ~1419.5 Da) derived from a protein found in human gastric juice. In rodent tissue-repair models it accelerated healing of a fully transected Achilles tendon across biomechanical, functional, and microscopic measures at 10 microg/kg [1], and it is pro-angiogenic by up-regulating VEGFR2 with downstream Akt-eNOS signaling [2]. The second specimen is TB-500, a synthetic N-acetylated heptapeptide (Ac-LKKTETQ, ~889.0 Da) corresponding to the actin-binding region — residues 17-23 — of the 43-residue protein Thymosin Beta-4. Its LKKTETQ motif binds monomeric G-actin in a 1:1 complex and sequesters it, regulating the cytoskeletal dynamics that drive cell migration [3][4]. One caveat carries through everything that follows: most efficacy data attributed to "TB-500" were generated with full-length Thymosin Beta-4 (~4963 Da), not the 7-mer [4][7]. The honest reading of each leg, and the missing combination evidence, runs through [BPC-157 vs TB-500 mechanisms](/research). ## BPC-157 and TB-500: the two peptides in the Wolverine blend BPC-157 and TB-500 are paired because each addresses a different node of tissue repair, and the blend's whole identity rests on that division of labor. The pairing is best read one specimen at a time before any claim about the two together [2][3]. BPC-157 holds the cytoprotective and pro-angiogenic node — VEGFR2-Akt-eNOS angiogenesis, nitric-oxide modulation, and growth-hormone-receptor-driven fibroblast proliferation [2]. TB-500 holds the cytoskeletal node — 1:1 G-actin sequestration via the LKKTETQ motif, regulating the cell migration and re-epithelialization that resurface a wound [3][4]. The two are described as acting through complementary but largely non-overlapping pathways, which is the basis of the "synergy" claim and the reason researchers pair them. That rationale is unpacked, with its missing evidence, on [the combination-rationale and synergy claim](/research). ### What is the Wolverine peptide blend? The Wolverine peptide blend is a research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair "stack." It is not a single chemical entity or an approved product; it carries no single molecular weight or CAS number [1][3]. The search term's volume is heavily conflated with the comic-book character — this site is the peptide-blend reading, not the fictional one. ### What is BPC-157 and TB-500? BPC-157 is a synthetic 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region, residues 17-23, of Thymosin Beta-4 [1][3]. The blend combines the two as a tissue-repair stack; it is not a single molecule or an approved product. ### What is the difference between BPC-157 and TB-500? BPC-157 is a 15-amino-acid gastric-juice-derived cytoprotective and pro-angiogenic peptide; TB-500 is a 7-amino-acid actin-binding fragment of Thymosin Beta-4 acting on cytoskeletal migration [1][3]. Different sequences, different molecular weights, different mechanisms — which is why they are presented as two distinct specimens rather than one substance. ## The BPC-157 TB-500 stack: what it is and what it is not The BPC-157 TB-500 stack assembles two separately characterized repair signals into one vial. On the evidence, the two halves differ in maturity but match in one respect: neither has been tested as part of the blend [8][9]. BPC-157's record is the more developed. A 2025 systematic review of BPC-157 in orthopaedic sports medicine catalogued 36 studies — 35 preclinical, exactly one human — found "no clinical safety data," and rated the evidence at the lowest tiers, level IV-V [8]. A 2025 narrative review reached the same reading: broad preclinical support, only three small human pilot studies, and a recommendation to treat BPC-157 as investigational given regulatory controversy and non-regulated availability [10]. TB-500's record leans on its parent protein. Thymosin Beta-4 binds actin, promotes cell migration, reduces myofibroblast number, and promotes angiogenesis [4]; the synthetic heptapeptide sold as TB-500 was characterized as the Ac-17-23 fragment for doping-control reference [7], but the bulk of the efficacy data was generated with the full-length protein. The assembled product sits on top of both records without adding to either: no peer-reviewed study has tested the combined BPC-157 plus TB-500 blend for any indication [8]. The 2026 Sports Medicine review of approved and unapproved musculoskeletal peptides lists both compounds, notes favorable animal-model outcomes, and cautions that rigorous human safety data are scarce, with potential for serious harm [9]. The honest-risk reading is laid out in [BPC-157 TB-500 side effects and safety research](/safety-research), and the studied research doses sit on [studied research doses (animal models)](/dosage). ## How this brief reads the blend The discipline of this site is to read each specimen against its own studies and to refuse to let a claim about the two together borrow credibility from either alone. A finding from BPC-157 is a BPC-157 finding; a finding from Thymosin Beta-4 is a Thymosin Beta-4 finding; and a claim about the combination is, at present, an empty entry on the record [8]. That discipline matters most where safety is concerned. The principal theoretical concern is a pro-angiogenic, pro-migratory tumor signal associated with Thymosin Beta-4 — the same properties that aid repair could, in theory, support tumor progression, and that is the kind of signal that compounds rather than cancels when two pro-repair peptides are combined [4]. The full reading sits at [the Thymosin Beta-4 tumor/angiogenesis safety signal](/safety-research). The pages ahead present the record straight: the mechanism literature on [BPC-157 vs TB-500 mechanisms](/research), the honest safety reading on [BPC-157 TB-500 side effects and safety research](/safety-research), the animal-model dose context on [studied research doses (animal models)](/dosage), the present-tense regulatory picture on [Wolverine legal status and 503A compounding](/legal-status), the [frequently asked questions about the blend](/faq), and [the full reference list](/references). --- Two peptides set on one studio table and shown straight — BPC-157 and TB-500 lit specimen by specimen, the Thymosin Beta-4 tumor signal and the 503A status left in plain view, with no clinic behind the lens and nothing here dispensed.